STOCK TITAN

Co-Diagnostics sets 1-for-25 reverse split for Nov. 24

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Co-Diagnostics, Inc. (CODX) will effect a 1-for-25 reverse stock split on November 24, 2026; its shares will begin split-adjusted trading when the market opens that day. The company said the split is intended to help maintain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing and maintain authorized shares available for potential equity financings.

Based on 13,044,465 shares currently outstanding, Co-Diagnostics expects approximately 521,779 shares outstanding after the split. The authorized share count will remain unchanged. Fractional shares will be rounded up to one whole share, and outstanding options and warrants will be adjusted under their terms, including fewer underlying shares and higher exercise prices.

Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Reverse stock split ratio 1-for-25 Effective November 24, 2026
Common shares outstanding 13,044,465 shares Described as currently outstanding before the reverse split
Expected common shares outstanding Approximately 521,779 shares Expected following the reverse split
Minimum bid price requirement $1.00 Nasdaq continued-listing requirement cited by the company
reverse stock split technical
"effect a reverse stock split of its issued and outstanding common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
split-adjusted basis technical
"begin trading on a split-adjusted basis"
An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.
fractional shares technical
"No fractional shares will be issued in connection with the Reverse Stock Split"
Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.
exercise price financial
"corresponding increase in the applicable exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
minimum bid price requirement regulatory
"maintain compliance with the $1.00 minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Split Ratio 1-for-25 reverse split
Effective Date November 24, 2026
Shares Before Split 13,044,465
Shares After Split 521,779

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does CODX’s 1-for-25 reverse stock split take effect?

The 1-for-25 split takes effect November 24, 2026, when the shares are expected to begin trading on a split-adjusted basis at market open.

How many CODX shares are expected to remain outstanding after the reverse split?

Co-Diagnostics expects approximately 521,779 shares to be outstanding after the split, based on 13,044,465 shares currently outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 0001692415 0001692415 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): November 19, 2026

 

CO-DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-38148

 

Utah   46-2609363
(State or other jurisdiction   (IRS Employer
of incorporation)   Identification Number)

 

2401 S. Foothill Drive, Suite D

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 438-1036

 

Former name or former address, if changed since last report: Not Applicable

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CODX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.03 - Material Modification to Rights of Security Holders.

 

As previously disclosed, on November 13, 2026, at a special meeting of the stockholders of Co-Diagnostics, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by the Company’s board of directors (the “Board”) at any time within twelve months following the special meeting, without further approval or authorization of the stockholders.

 

On November 13, 2026, the Company’s Board approved a reverse stock split ratio of 1-for-25. The Company filed Articles of Amendment to the Company’s Articles of Incorporation, as amended (the “Amendment”) with the Utah Division of Corporations and Commercial Code on November 19, 2026, which will be effective at 12:01 a.m. Mountain Time on Tuesday, November 24, 2026. The Company’s shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market commencing upon market open on November 24, 2026. A copy of the Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference. This discussion is qualified in its entirety by reference to the full text of the Amendment.

 

As a result of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share of common stock, par value $0.001 per share. The Company will not issue any fractional shares in connection with the reverse stock split. Instead, each stockholder who would otherwise be entitled to receive a fractional share will receive one whole share of common stock in lieu of such fractional share. The reverse stock split will not modify the rights or preferences of the common stock. The reverse stock split will also not change the number of shares of capital stock authorized for issuance under our Articles of Incorporation.

 

Immediately after the reverse stock split becomes effective, there will be approximately 521,779 shares of common stock issued and outstanding. The common shares will trade under a new CUSIP number, 189763 303, effective November 24, 2026, and continue to trade under the symbol “CODX.” All stock options and warrants of the Company outstanding immediately prior to the reverse stock split will be proportionally adjusted in accordance with their respective terms.

 

The Company has appointed its transfer agent, VStock Transfer, LLC, to act as exchange agent for the reverse stock split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 7.01. Regulation FD. Disclosure.

 

On November 19, 2026, the Company issued a press release announcing the reverse stock split. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
3.1   Articles of Amendment to the Articles of Incorporation of Co-Diagnostics, Inc.
99.1   Press release dated November 19, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CO-DIAGNOSTICS, INC.
         
Date: November 19, 2026   By: /s/ Daniel Bohrer
        Daniel Bohrer
        Executive Vice President Finance & Accounting (Principal Financial and Accounting Officer)

 

 

 

Exhibit 99.1

 

Co-Diagnostics Announces Reverse Stock Split

 

SALT LAKE CITY, Nov. 19, 2026 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Diagnostics” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed Articles of Amendment to its Articles of Incorporation (the “Amendment”) to effect a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-25 shares (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. ET on Tuesday, November 24, 2026. The Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “CODX” and will begin trading on a split-adjusted basis when the market opens on Tuesday, November 24, 2026. The Reverse Stock Split is intended to enable the Company to maintain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, and to maintain sufficient authorized shares available for issuance to allow the Company to conduct equity financings as needed. The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 189763 303.

 

At the Special Meeting of Stockholders held on November 13, 2026 (the “Special Meeting”), the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by the Company’s board of directors at any time within twelve months following the Special Meeting, without further approval or authorization of the stockholders. Additional information regarding the Reverse Stock Split approved by stockholders can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on October 26, 2026.

 

The Amendment provides that at the effective time of the Reverse Stock Split, each 25 shares of the Company’s issued and outstanding common stock will be automatically combined into one (1) validly issued, fully paid and non-assessable share of common stock, without effecting a change to the par value per share. The Reverse Stock Split will impact all shares of the Company’s common stock outstanding immediately prior to the effective time of the Reverse Stock Split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the Reverse Stock Split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split with a corresponding increase in the applicable exercise price per share, in each case in accordance with the terms thereof. The Reverse Stock Split will not change the number of shares of capital stock authorized for issuance under our Articles of Incorporation. Based on the 13,044,465 shares of common stock currently outstanding, we expect approximately 521,779 shares of common stock to be issued and outstanding following the Reverse Stock Split.

 

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will have those shares rounded up to the next whole share. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company’s transfer agent, VStock Transfer, LLC.

 

About Co-Diagnostics, Inc.:

 

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that implementing a reverse stock split will result in the Company maintaining compliance with Nasdaq listing requirements or that the Company will be able to conduct equity financings in the future. A discussion of additional risks and uncertainties can be found in the Company’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 31, 2026, and in the Company’s other filings with the SEC, including Quarterly Reports on Form 10-Q. Co-Diagnostics undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this press release.

 

For further information: Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, +1 212.896.1254, CODX@KCSA.com; Media Contact: Jennifer Webb, ColtrinMethod PR, jcoltrin@coltrinmethodpr.com.

 

 

Filing Exhibits & Attachments

5 documents

Keep reading